Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer

No abstract is available for this paper.

• Publication year

  2013

• Venue

  The Prostate

• Publication date

  2013-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/pros.22620PMID 23192371
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment?

  2013cited by this paper
• Role of monocarboxylate transporters in human cancers: state of the art

  2012cited by this paper
• Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer

  2011cited by this paper
• Targeting cancer metabolism: a therapeutic window opens

  2011cited by this paper
• The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

  2010cited by this paper
• Is triple immunostaining with 34betaE12, p63, and racemase in prostate cancer advantageous? A tissue microarray study.

  2007cited by this paper
• Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens.

  2005cited by this paper
• The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

  2005cited by this paper
• Diagnostic Utility of Immunohistochemical Staining for p63, a Sensitive Marker of Prostatic Basal Cells

  2002cited by this paper
• Expression of &agr;-Methylacyl-CoA Racemase (P504S) in Atypical Adenomatous Hyperplasia of the Prostate

  2002cited by this paper
• AJCC Cancer Staging Manual

  2002cited by this paper
• Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer.

  2001cited by this paper
• Globocan 2000 : cancer incidence, mortality and prevalence worldwide

  2001cited by this paper
• p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.

  2001cited by this paper
• The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies.

  2001cited by this paper
• Delineation of prognostic biomarkers in prostate cancer

  2001cited by this paper
• P504S: A New Molecular Marker for the Detection of Prostate Carcinoma

  2001cited by this paper
• Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.

  2001cited by this paper
• In Mouse α-Methylacyl-CoA Racemase, the Same Gene Product Is Simultaneously Located in Mitochondria and Peroxisomes*

  2000cited by this paper
• Subcellular localization and physiological role of alpha-methylacyl-CoA racemase.

  2000cited by this paper
• p63 is a prostate basal cell marker and is required for prostate development.

  2000cited by this paper
• Increasing incidence of minimal residual cancer in radical prostatectomy specimens.

  1997cited by this paper
• Benign mimics of prostatic adenocarcinoma on needle biopsy.

  1997cited by this paper
• Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy.

  1995cited by this paper
• The Utility of Basal Cell—Specific Anti‐Cytokeratin Antibody (34βE12) in the Diagnosis of Prostate Cancer: A Review of 228 Cases

  1995cited by this paper

• Targeting glycolysis in prostate cancer: Molecular mechanisms and therapeutic advances.

  2026cites this paper
• AMACR is a highly sensitive and specific immunohistochemical marker for diagnosing prostate cancer on biopsy: a systematic review and meta-analysis

  2025cites this paper
• Association between the Expression of Monocarboxylate Transporters in Tumors and Surrounding Stromal Cells and Cancer Prognosis: A Meta-Analysis.

  2025cites this paper
• Lactylation-related gene signature accurately predicts prognosis and immunotherapy response in gastric cancer

  2024cites this paper
• Decreased SLC16A13 Expression Level Can Increase Apoptosis in KATO2 Cell Line, A Promising Biomarker

  2024cites this paper
• Atorvastatin Exerts More Selective Inhibitory Effects on hMCT2 than on hMCT1 and hMCT4

  2023cites this paper
• Clinical and Prognostic Impact of the Warburg Effect in Esophageal Carcinoma: Monocarboxylate Transporters as Candidates for Therapeutic Targeting

  2023cites this paper
• Membrane transporters in cell physiology, cancer metabolism and drug response

  2023cites this paper
• A systemic analysis of monocarboxylate transporters in ovarian cancer and possible therapeutic interventions

  2023cites this paper
• Prognostic Value of Monocarboxylate Transporter 1 Overexpression in Cancer: A Systematic Review

  2023cites this paper
• Novel MOG analogues to explore the MCT2 pharmacophore, α-ketoglutarate biology and cellular effects of N-oxalylglycine

  2022cites this paper
• Exploration of metabolic responses towards hypoxia mimetic DMOG in cancer cells by using untargeted metabolomics

  2022cites this paper
• Role of monocarboxylate transporters and glucose transporters in prostate cancer

  2022cites this paper
• Publisher Correction: MOG analogues to explore the MCT2 pharmacophore, α-ketoglutarate biology and cellular effects of N-oxalylglycine

  2022cites this paper
• In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment

  2021cites this paper
• Fets et al . – MOG analogues 1 Development of novel MOG analogues with increased stability to explore 1 MCT 2 and α-ketoglutarate biology in vivo 2 3

  2021cites this paper
• Identification of the essential extracellular aspartic acids conserved in human monocarboxylate transporters 1, 2, and 4.

  2020cites this paper
• Targeting lactate production and efflux in prostate cancer.

  2020cites this paper
• Comprehensive analysis of the SLC16A gene family in pancreatic cancer via integrated bioinformatics

  2020cites this paper
• Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease

  2020cites this paper
• Prostate Cancer Proliferation Is Affected by the Subcellular Localization of MCT2 and Accompanied by Significant Peroxisomal Alterations

  2020cites this paper
• Role of monocarboxylate transporters in the diagnosis, progression, prognosis, and treatment of prostate cancer.

  2020cites this paper
• Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma

  2019cites this paper
• CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells

  2019cites this paper
• Identification of novel common variants associated with chronic pain using conditional false discovery rate analysis with major depressive disorder and assessment of pleiotropic effects of LRFN5

  2018cites this paper
• Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy

  2018cites this paper
• Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities.

  2018cites this paper
• MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG

  2018cites this paper
• Investigating the effects of lycopene and green tea on the metabolome of men at risk of prostate cancer: The ProDiet randomised controlled trial

  2018cites this paper
• Value of pH regulators in the diagnosis, prognosis and treatment of cancer.

  2017influential citation
• Adipocytes promote malignant growth of breast tumours with monocarboxylate transporter 2 expression via β-hydroxybutyrate

  2017cites this paper
• Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer

  2017cites this paper
• Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas.

  2016cites this paper
• Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in Disease

  2016cites this paper
• Isolation and purification of STEAP 1 protein fragment in Escherichia coli cells : a potential target for prostate cancer

  2016cites this paper
• Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer

  2015cites this paper
• 3-Bromopyruvate induces rapid human prostate cancer cell death by affecting cell energy metabolism, GSH pool and the glyoxalase system

  2015cites this paper
• 1 Biology of Human Tumors Q 1 2 T-box Transcription Factor Brachyury Is Associated with 3 Prostate Cancer Progression and Q 2 Aggressiveness 4 5

  2015cites this paper
• Proton channels and exchangers in cancer.

  2015cites this paper
• A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy

  2015cites this paper
• Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer

  2015cites this paper
• Monocarboxylate transporters as targets and mediators in cancer therapy response.

  2014cites this paper
• Microfluidic platforms for discovery and detection of molecular biomarkers

  2014cites this paper
• Microfluidic platforms for discovery and detection of molecular biomarkers

  2014cites this paper
• STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.

  2014cites this paper
• Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know?

  2014cites this paper
• T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness

  2014cites this paper
• Molecular Markers for Prostate Cancer in Formalin-Fixed Paraffin-Embedded Tissues

  2013cites this paper
• The Effect of MCT1 and MCT4 silencing on Prostate Cancer Survival and Aggressiveness

  2013cites this paper
• Correction: A-Methylacyl-CoA Racemase (AMACR) and Prostate-Cancer Risk: A Meta-Analysis of 4,385 Participants

  2013cites this paper
• A-Methylacyl-CoA Racemase (AMACR) and Prostate-Cancer Risk: A Meta-Analysis of 4,385 Participants

  2013cites this paper
• Personalized Medicine in Screening for Malignant Disease: A Review of Methods and Applications

  2013cites this paper
• Diagnostic and Prognostic Value of Lactate Transporters in Prostate Cancer

  2013cites this paper